Trials / Unknown
UnknownNCT04088058
A Phase II Open-label Single-arm Study to Evaluate the Efficacy and Safety of ADSCs in Subjects With Liver Cirrhosis
Adipose-Derived Stem Cells (ADSCs) Injections for Liver Cirrhosis
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Gwo Xi Stem Cell Applied Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the investigators study was to investigate the safety and efficacy of autologous ADSCs for the clinical treatment of liver cirrhosis.
Detailed description
One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GXHPC1 | autologous ADSCs |
Timeline
- Start date
- 2019-11-16
- Primary completion
- 2025-04-19
- Completion
- 2025-04-19
- First posted
- 2019-09-12
- Last updated
- 2023-04-10
Locations
2 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT04088058. Inclusion in this directory is not an endorsement.